Protocol Ledger

Therapeutic Cohort NEU · ClinicalTrials.gov API v2

Neurology, Psychiatry, and Pain: Phase II & III Clinical Trial Benchmarks

Protocol Ledger tracks 4,809 interventional Phase II and Phase III Neurology, Psychiatry, and Pain protocols registered from 2018 through 2026, including 1,909 active studies, 1,763 completed studies, and 628 early-stopped studies (13.06% overall; 26.27% of closed trials).

Median Enrollment: 84.0 participants Median Completed Span: 714 days California Share: 1,121 studies (23.3%)

1. Reconciled Neurology, Psychiatry, and Pain Execution & Stop-Cause Profile

Neurology, Psychiatry, and Pain Cohort Metrics (Publication 47c4426df7e9d67d5bfe)
Clinical Trial Metric Verified Value Operational Context
Total Phase II & III Protocols (2018 to 2026) 4,809 Deterministic primary MeSH and condition-keyword assignment
Active Concurrent Pipeline 1,909 Recruiting, enrolling by invitation, and active follow-up protocols
Completed vs Prematurely Stopped 1,763 / 628 26.27% closed-trial attrition ratio across 2,391 closed protocols
Slow Accrual vs Safety & Futility Stops 137 / 68 / 54 Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5)
Physical Hospital Site Disclosure Rate 86.4% Named hospital campus participations vs anonymized CRO site slots

2. Leading Consolidated Trial Sponsors Focused on Neurology, Psychiatry, and Pain

Consolidated Biopharma, Academic & Federal Sponsors (Neurology, Psychiatry, and Pain Primary Focus)
Sponsor Hub Sector Protocols Active Completed FDA NDA/BLA
VA Office of Research and Development Federal / Public Agency 112 59 34 0
Brigham and Women's Hospital Academic / Institutional Sponsor 106 49 36 0
Beijing Tiantan Hospital Academic / Institutional Sponsor 86 41 22 0
Medical University of South Carolina Academic / Institutional Sponsor 74 33 31 0
Chang Gung Memorial Hospital Academic / Institutional Sponsor 70 28 12 0
University of Calgary Academic / Institutional Sponsor 65 33 6 0
Biogen Biopharma Industry 61 22 19 12
Otsuka Pharmaceutical Development & Commercialization Biopharma Industry 58 16 33 0
Kafrelsheikh University Academic / Institutional Sponsor 51 11 17 0
Capital Medical University Academic / Institutional Sponsor 47 18 10 0
Neurocrine Biosciences Biopharma Industry 46 19 17 4
University of British Columbia Academic / Institutional Sponsor 42 14 6 0

3. Representative Multi-Center Phase II & III Neurology, Psychiatry, and Pain Studies

Indexed ClinicalTrials.gov v2 Study Dossiers in Neurology, Psychiatry, and Pain
NCT Study Protocol Brief Title Sponsor Phase Status
NCT07325292 Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis Sanofi Phase III RECRUITING
NCT04302870 Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial University of Edinburgh Phase II/III RECRUITING
NCT06290141 A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sanofi Phase III RECRUITING
NCT04965675 A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine H. Lundbeck Phase III RECRUITING
NCT07174310 A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease Roche / Genentech Phase III RECRUITING
NCT04867317 Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) VA Office of Research and Development Phase III RECRUITING
NCT07687706 Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke) Hanyang University Guri Hospital Phase III RECRUITING
NCT07430956 Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable Regeneron Pharmaceuticals Phase III RECRUITING
NCT07792681 Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults Brise Pharmaceuticals Co Phase II/III RECRUITING
NCT07218354 Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE) VA Office of Research and Development Phase III RECRUITING
NCT06157502 Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY) Beijing Tiantan Hospital Phase III RECRUITING
NCT06315231 Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients Simcere Pharmaceutical Co Phase II RECRUITING
NCT07721961 A Study of MI078 for Postpartum Depression Nanjing Minova Pharmaceutical Co Phase III RECRUITING
NCT07777861 A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy Qingdao WanMing BioCell Pharmaceutics Co Phase II RECRUITING
NCT07262645 Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A) Danyang Huichuang Medical Equipment Co Phase III RECRUITING
NCT07219953 A Study of Brenipatide in Participants With Alcohol Use Disorder Eli Lilly and Company Phase III RECRUITING

Related Therapeutic Condition Hubs & Crosswalks

Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Immunology, Rheumatology, and Dermatology, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI